| Autor: |
Alan Jay Katz, Josephine eKang |
| Jazyk: |
angličtina |
| Rok vydání: |
2014 |
| Předmět: |
|
| Zdroj: |
Frontiers in Oncology, Vol 4 (2014) |
| Druh dokumentu: |
article |
| ISSN: |
2234-943X |
| DOI: |
10.3389/fonc.2014.00240 |
| Popis: |
Objectives: Stereotactic body radiation therapy (SBRT) takes advantage of the prostate’s low α/β ratio to deliver a large radiation dose in few fractions. Initial studies on small groups of low-risk patients support SBRT’s potential for clinical efficacy while limiting treatment-related morbidity and maintained quality of life (QOL). This prospective study expands upon prior studies to further evaluate SBRT efficacy for a large patient population with organ confined, low- and intermediate-risk prostate cancer patients. Methods: 477 patients with prostate cancer received CyberKnife SBRT. The median age was 68.6 years and the median PSA was 5.3 ng/ml. 324 patients were low-risk (PSA < 10 ng/ml and Gleason < 7), 153 were intermediate-risk (PSA 10-20 ng/ml or Gleason = 7). Androgen deprivation therapy was administered to 51 patients for up to six months. 154 patients received 35 Gy delivered in 5 daily fractions; the remaining patients received a total dose of 36.25 Gy in 5 daily fractions. Biochemical failure was assessed using the Phoenix criterion. Results: Median follow up was 72 months. The median PSA at 7 years was 0.11 ng/ml. Biochemical failures occurred for 11 low-risk patients (2 locally), 14 intermediate-risk patients (3 locally). The actuarial 7-year freedom from biochemical failure was 95.6% and 89.6% for low- and intermediate-risk groups, respectively (p < 0.012). Among patients with intermediate-risk disease, those considered to have low intermediate-risk (Gleason 6 with PSA>10, or Gleason 3+4 with PSA |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
